How FDA assigns primary mode of action and lead center for combination products Understanding FDA’s Assignment of Primary Mode of Action and Lead Center for Combination Products Introduction to Combination Products Combination products are defined by the US Food and Drug Administration (FDA) as therapeutic and diagnostic products that combine drugs, devices, and/or biological products. According to FDA regulations, these products must meet the regulatory standards applicable to both their constituent parts, thereby requiring specialized knowledge and compliance strategies from regulatory professionals. The classification and regulation of combination products are critical, as they can significantly affect not only market entry…

Regulatory Pathways for Drug-Device and Biologic-Device Combination Products In the rapidly evolving landscape of healthcare, combination products that integrate both drugs and devices, as well as biologics and devices, have become increasingly significant. The U.S. Food and Drug Administration (FDA) has established regulatory pathways to ensure the safety and efficacy of these products. This tutorial aims to guide regulatory, quality, clinical, and RA/QA professionals through the complexities of these regulations, providing an in-depth understanding of the pathways and compliance requirements necessary for approval in the U.S., UK, and EU markets. Understanding Combination Products A combination product is defined as a…

Global Alignment of US FDA Combination Product Rules with EU Regulations In today’s rapidly evolving regulatory landscape, understanding the intersection of US FDA combination product regulations and EU frameworks is critical for professionals working in the field of medical devices, drugs, and biologics. This article offers a comprehensive guide to the combined regulatory pathways for combination products in the US, UK, and EU, emphasizing critical aspects such as primary mode of action, coordination between the Office of Pharmaceutical Quality (OPQ) and the Center for Devices and Radiological Health (CDRH), and the essential considerations for good manufacturing practices (GMP) and post-market…

Combination Product Quality Systems and the QSIT Inspection Model The increasing complexity of combination products, which integrate drugs, devices, and biological products, necessitates a robust understanding of the regulatory frameworks ensuring their safety and efficacy. As regulatory professionals in the pharmaceutical and medical device sectors, it is critical to comprehend how to adequately apply quality systems within combination products and how these systems are evaluated during inspections, particularly through the Quality System Inspection Technique (QSIT). This article provides a step-by-step tutorial on the quality systems applicable to combination products and the QSIT model used by the FDA. Understanding Combination Products…

Strategies for Platform Devices Used with Multiple Drugs or Biologics This comprehensive tutorial will provide regulatory professionals with a step-by-step guide on the strategies for managing combination products that incorporate platform devices used with multiple drugs or biologics. Specifically, the focus will be on the regulatory pathways designed for these products, ensuring compliance with FDA regulations, and navigating the complexities these products entail. This guide is particularly relevant for professionals working within the realms of regulatory affairs, quality assurance, clinical, and quality control in the context of medical devices. Understanding Combination Products The FDA classifies products that combine drugs, devices,…

Post Market Safety Reporting Rules for Combination Products and Their Components Understanding the complexities of post-market safety reporting for combination products is essential for regulatory, quality, clinical, and RA/QA professionals involved in medical devices and combination products. The U.S. Food and Drug Administration (FDA) mandates specific reporting guidelines that ensure public safety and product efficacy. This guide aims to provide a comprehensive overview of the rules, focusing on the regulatory pathways, coordination between offices, and the significance of post-market safety reporting. 1. Overview of Combination Products Combination products are defined by the FDA as products that are composed of two…

Bridging Drug and Device Stability, Shelf Life and Packaging Information Introduction to Combination Products Combination products are defined by the U.S. Food and Drug Administration (FDA) as products that combine a drug, a device, or biological product. Understanding the interplay between these components is essential, particularly regarding stability, shelf life, and packaging information. The FDA classifies these products based on their primary mode of action (PMOA), which can significantly influence regulatory pathways and requirements. In this comprehensive guide, we will delve into the nuances of ensuring compliance in these critical areas of combination products. Our exploration will include the regulatory…

Introduction to Combination Products: Drug-Device and Biologic-Device Regulatory Pathways The convergence of digital health technologies with traditional medical devices, drugs, and biologics has become increasingly prevalent. Combination products—defined by the FDA as therapeutic and diagnostic goods that combine a drug with a device, or device with a biologic—present distinct regulatory challenges and opportunities. This tutorial intends to guide professionals in the regulatory affairs, quality assurance, and clinical sectors through the intricate landscape of combination product regulations set forth by the U.S. Food and Drug Administration (FDA), focusing specifically on the pathways for authorization. Regulatory frameworks, including the guidance on combination…

Risk Management and FMEA for Drug and Device Failure Modes Risk Management and FMEA that Spans Both Drug and Device Failure Modes Introduction to Combination Products Regulatory Pathways Combination products, which integrate drugs, devices, and biological products, present unique regulatory challenges for professionals in the fields of quality assurance (QA), regulatory affairs (RA), and clinical development. The United States Food and Drug Administration (FDA) categorizes these products based on their primary mode of action (PMOA)—the main intended purpose of the combination product. Understanding how to manage risks associated with both drugs and devices is crucial for compliance with FDA regulations….

Governance for Cross-Functional Decision Making on Combination Development In the increasingly complex landscape of combination products—comprising both drug-device and biologic-device regulatory pathways—effective governance is critical. This article provides a comprehensive step-by-step tutorial on governance structures, regulatory considerations, and decision-making processes that facilitate successful development and compliance with U.S. FDA regulations. It aims to equip regulatory affairs, quality assurance, and clinical professionals with the essential knowledge needed to navigate the intricacies surrounding combination products. Understanding Combination Products Combination products comprise two or more regulated components—typically a drug and a device or a biologic and a device—packaged together or presented as a…